Why did the FDA reverse course on Moderna's flu shot?

Regulators reopened review after initial refusal

Regulatory officials agreed to review an mRNA influenza vaccine from Moderna after an earlier announcement that the agency would not accept the company’s application. The U.S. regulator’s change of position followed further discussions between the company and reviewers; Moderna said those talks prompted the agency to accept the submission for consideration.

What happened

• The agency initially signalled it would not consider the application, an unusual step that raised industry eyebrows.
• Moderna engaged in additional dialogue with regulators and subsequently reported that the application would be reviewed.
• The reversal drew attention because it came amid broader turmoil at federal health agencies, including high‑profile leadership changes and policy shifts that have already unsettled vaccine makers.

Why it matters

Decisions on novel vaccine platforms set precedents for how regulators evaluate new technology and product dossiers. The back‑and‑forth delayed clarity for clinicians, health systems and patients about whether a new mRNA flu option will become available. It also highlighted two broader vulnerabilities: first, that regulatory processes can be disrupted by communication breakdowns or procedural disputes; and second, that industry confidence can be fragile when federal policy and leadership are in flux. For vaccine manufacturers, a transparent and predictable review pathway is critical for investment and planning. For the public, delays and uncertainty can slow access to potentially improved vaccines and complicate seasonal immunisation campaigns.